



RECEIVED

JAN 28 2003

1632

PTO/SB/21 (08-00)

Approval for use through 10/31/2002. OMB 0651-0031

TECH CENTER 1600 2000

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Application Number	09/750,456
Filing Date	Dec 28, 2000
First Named Inventor	Friedrich, Glenn
Group Art Unit	1632
Examiner Name	Anne-Marie Falk

Total Number of Pages in This Submission

6

Attorney Docket Number

LEX-0286-USA

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	- Return Postcard
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	- Response to Restriction and Election Requirement with Exhibits A and B
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Lexicon Genetics Incorporated
	Lance K. Ishimoto Reg. No. 41,866
Signature	
Date	January 17, 2003



24231

PATENT TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Arlington, VA 22202 on this date: January 17, 2003

Typed or printed name	Michelle Klein		
Signature		Date	January 17, 2003



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Friedrich *et al.* Group Art Unit: 1632
Application No.: 09/750,456 Examiner: Anne Marie Falk
Filed: 12/28/00 Attorney Docket No.:
Title: Novel Mutated Mammalian Cells and Animals LEX-0286-USA

**AMENDMENT AND RESPONSE TO RESTRICTION AND ELECTION
REQUIREMENTS**

Commissioner for Patents
Arlington, VA 22202

Sir:

RECEIVED

JAN 28 2003

TECH CENTER 1800, 2500

The Examiner is respectfully requested to enter the following amendments. A response to the Sequence Election Requirement mailed December 17, 2002 ("the Requirement" Paper No. 12) is also included herewith and the Examiner is respectfully requested to consider the remarks therein. The response is timely filed. Applicants believe no fee in addition to the fee for the extension of time is due in connection with this response. However, the Commissioner is authorized to charge any underpayment or credit any overpayment to Deposit Account No. 50-0892.

AMENDMENT

In the claims:

Please amend Claims 1 and 7 as follows:

1 (amended). A genetically engineered mammalian cell that has been mutated by a process comprising the insertion of a recombinantly manipulated polynucleotide sequence into a gene in said genetically engineered mammalian cell wherein said gene is identifiable as corresponding to SEQ ID NO: 393.

